11:18 AM EDT, 07/29/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) said Monday it has dosed the first person with a subcutaneous formulation of sabirnetug in a phase 1 study of the drug to potentially treat early Alzheimer's disease.

The trial will compare the pharmacokinetic between subcutaneous and intravenous administrations of the candidate drug in healthy people, the company said.

Acumen said it's also enrolling patients in a phase 2 trial to assess the efficacy and safety of intravenous sabirnetug in people with early Alzheimer's disease.

Price: 3.24, Change: -0.25, Percent Change: -7.04